Soliris®

Active substance eculizumab
Holder Alexion
Status Running
Indication patients with refractory generalized myasthenia gravis (rgMG) who completed the study ECU-MG-302 (Open label extension) and, in the opinion and the clinical judgement of the treating physician would continue to benefit from a treatment with Eculizumab (Soliris®) which is not yet commercially available for this indication in Belgium.
Public documents Approbation
  Information for the patient
  Informed consent
Last update 10/08/2022

 

Last updated on 28/09/2022